ACELYRIN - SLRN Enterprise Value-to-Revenue Multiple

acelyrin.com (SLRN) - corporate logo

Acelyrin, Inc. (SLRN) possesses significant pricing power due to innovative proteins that effectively block interleukin-17A. The immediate growth driver will be the results of final trials for anti-inflammatory molecules. After examining the firm's EV/Sales multiple valuation on GURU.Markets, we find that determines the latest valuation metric. Supply stability is guaranteed by strict adherence to temperature controls during the transportation of immunological drugs to clinics.

ACELYRIN (SLRN) - Company Value to Revenue from 07/04/2022 to 11/20/2026

ACELYRIN Inc. - analytical breakdowns and key metrics (SLRN)

- market value and analyst target forecast:
Initial company analysis:ACELYRIN, SLRN
Product sample of ACELYRIN, Inc.

This indicator measures the ratio of total enterprise value to annual sales, excluding the impact of debt to identify the actual market overvaluation of assets. By analyzing the enterprise value-to-revenue level on GURU.Markets, an investor can assess whether the capitalization of Acelyrin, Inc. (SLRN) is justified, given the colossal R&D expenditures and prolonged clinical trials of immunological drugs prior to their commercialization.

Direct competitors

HLN: Enterprise Value-to-Revenue Ratio|Kenvue Corp (KVUE) - Enterprise Value-to-Revenue Ratio|Verona Pharma PLC - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Jyong Biotech Ltd|EV/Sales Multiple Ligand Corp|EV/Sales Multiple AMRX|Total Company Value-to-Revenue Ratio Perrigo Company plc|EV/Sales Multiple ALVO (Alvotech Biopharmaceuticals)|LQDA: Company Value to Revenue Ratio|Galapagos N.V. - EV/Sales Multiple|ANIP - EV/Sales Multiple|MNKD: EV/Sales Multiple|amphastar.com (AMPH) - EV/Sales Multiple|PCRX (Pacira Pharmaceuticals) - EV/Sales Multiple|Company Value to Revenue ARS Pharmaceuticals, Inc. (SPRY)|EV/Sales Multiple TBPH|AQST (Aquestive Therapeutics) - Business Value to Revenue|scPharmaceuticals, Inc. - Company Value to Revenue|Business Value to Revenue TECX|tonixpharma.com - EV/Sales Multiple|Business Value to Revenue SXTC (sxtchina.com)|Eupraxia Pharma (EPRX) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue BioHarvest|Company Value to Revenue EXOZ|Company Value to Revenue Oramed Pharmaceuticals (ORMP)|Company Value to Revenue ENTX (Entera Bio Corp)|MindWalk Holdings Inc. - Company Value to Revenue Ratio|EV/Sales Multiple ABVC (ABVC BioPharma Inc)|CPIX - Company Value to Revenue|Quantum BioPharma Corp - EV/Sales Multiple|FGEN (fibrogen.com) - Company Value to Revenue Ratio|TELO (Telomir Pharmaceuticals) - Company Value to Revenue|Rani Therapeutics Holdings - Business Value to Revenue|Company Value to Revenue SNYR|Enterprise Value-to-Revenue Multiple rallybio.com RLYB|EV/Sales Multiple LEXX|PULM (Pulmatrix, Inc.) - Business Value to Revenue|Pheton Holdings - Company Value to Revenue|EV/Sales Multiple Aptorum Group Limited APM|LYRA: Company Value to Revenue|IBO: Enterprise Value-to-Revenue Ratio|TNFA: EV/Sales Multiple|YCBD: Enterprise Value-to-Revenue Coefficient|Enterprise Value-to-Revenue Ratio PainReform Ltd|CYTO (altamiratherapeutics.com) - Enterprise Value-to-Revenue Coefficient|EV/Sales Multiple LIPO|OPTN - Enterprise Value-to-Revenue Multiple|Enterprise Value-to-Revenue Ratio pieris.com PIRS|Business Value to Revenue PROC|PTPI - Enterprise Value-to-Revenue Ratio|Qilian International Holding (QLI) - Company Value to Revenue|TFF Pharmaceuticals, Inc (TFFP) - Enterprise Value-to-Revenue Ratio